Toxicity of antiretroviral therapy and implications for drug development

被引:159
作者
Carr, A [1 ]
机构
[1] St Vincents Hosp, HIV Immunol & Infect Dis Clin Serv Unit, Sydney, NSW 2010, Australia
关键词
D O I
10.1038/nrd1151
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The toxicity of antiretroviral therapy is an increasingly important issue in the management of patients with human immunodeficiency virus (HIV). With sustained major declines in opportunistic complications, HIV infection is increasingly a more chronic disease, and so more drugs are being used in more patients for longer periods. However, permanent and near-perfect adherence to antretroviral therapy is needed to maximize its long-term benefits. Although adverse reactions to antiretroviral therapy are common, and profoundly affect its clinical efficacy by limiting adherence, many such reactions are poorly studied and analysed, and are under-reported. This article summarizes adverse events associated with antiretroviral therapy, and discusses weaknesses and possible solutions in the study, analysis and reporting of adverse events that could improve antiretroviral drug development.
引用
收藏
页码:624 / 634
页数:11
相关论文
共 105 条
[1]   Therapeutic drug monitoring - An aid to optimising response to antiretroviral drugs? [J].
Aarnoutse, RE ;
Schapiro, JM ;
Boucher, CAB ;
Hekster, YA ;
Burger, DM .
DRUGS, 2003, 63 (08) :741-753
[2]   Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal [J].
Altfeld, M ;
Rockstroh, JK ;
Addo, M ;
Kupfer, B ;
Pult, I ;
Will, H ;
Spengler, U .
JOURNAL OF HEPATOLOGY, 1998, 29 (02) :306-309
[3]   The revised CONSORT statement for reporting randomized trials: Explanation and elaboration [J].
Altman, DG ;
Schulz, KF ;
Moher, D ;
Egger, M ;
Davidoff, F ;
Elbourne, D ;
Gotzsche, PC ;
Lang, T .
ANNALS OF INTERNAL MEDICINE, 2001, 134 (08) :663-694
[4]  
Ammassari A, 2001, J ACQ IMMUN DEF SYND, V28, P445, DOI 10.1097/00042560-200112150-00006
[5]   Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance [J].
Bastard, JP ;
Caron, M ;
Vidal, H ;
Jan, V ;
Auclair, M ;
Vigouroux, C ;
Luboinski, J ;
Laville, M ;
Malachi, M ;
Girard, PM ;
Rozenbaum, W ;
Levan, P ;
Capeau, J .
LANCET, 2002, 359 (9311) :1026-1031
[6]   Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients [J].
Benhamou, Y ;
Bochet, M ;
Thibault, V ;
Di Martino, V ;
Caumes, E ;
Bricaire, F ;
Opolon, P ;
Katlama, C ;
Poynard, T .
HEPATOLOGY, 1999, 30 (05) :1302-1306
[7]   Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs - The Swiss HIV cohort study [J].
Bernasconi, E ;
Boubaker, K ;
Junghans, C ;
Flepp, M ;
Furrer, HJ ;
Haensel, A ;
Hirschel, B ;
Boggian, K ;
Chave, JP ;
Opravil, M ;
Weber, R ;
Rickenbach, M ;
Telenti, A .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 31 (01) :50-55
[8]   Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine [J].
Bessesen, M ;
Ives, D ;
Condreay, L ;
Lawrence, S ;
Sherman, KE .
CLINICAL INFECTIOUS DISEASES, 1999, 28 (05) :1032-1035
[9]  
Blanch J, 2001, J ACQ IMMUN DEF SYND, V27, P336, DOI 10.1097/00126334-200108010-00003
[10]   Predictors of protease inhibitor-associated adverse events [J].
Bonfanti, P ;
Ricci, E ;
Landonio, S ;
Valsecchi, L ;
Timillero, L ;
Faggion, I ;
Quirino, T .
BIOMEDICINE & PHARMACOTHERAPY, 2001, 55 (06) :321-323